Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common and serious complication following ERCP, with incidence rates ranging from 3% to 15% and up to 40% in high-risk patients. Its multifactorial pathogenesis involves both patient-related and procedure-related factors. Established risk factors include female sex, younger age, sphincter of Oddi dysfunction, previous pancreatitis, difficult cannulation, and pancreatic duct injection. The combination of several risk factors markedly increases the likelihood of PEP, underscoring the need for individualized risk assessment. Preventive strategies have evolved from empirical approaches to evidence-based interventions. Rectal non-steroidal anti-inflammatory drugs and prophylactic pancreatic duct stenting are strongly supported by clinical evidence as effective measures, particularly in high-risk patients. Aggressive intravenous hydration and early precut sphincterotomy have also shown benefit. However, the efficacy of pharmacological agents such as somatostatin, gabexate, and nafamostat mesilate remains inconsistent. Recent advances include the development of risk prediction models and scoring systems that integrate patient and procedural variables, offering moderate predictive accuracy. Ongoing research explores the use of artificial intelligence to improve risk stratification and guide prophylactic strategies. Future efforts should focus on standardizing diagnostic criteria, validating predictive tools, and optimizing combined preventive protocols. Through integrated risk assessment and tailored prevention, the incidence and severity of PEP may be significantly reduced, improving safety and outcomes in ERCP practice.